PCRI is a 501(c) (3)
Not-for-profit public charity
To Learn More:
PCRI Mission
PCRI Staff & Boards
New to PCRI
Basics of PC
Undiagnosed
Newly Diagnosed
Local Therapies
Systemic Therapies
Androgen Independent
High Risk PC
Treatment Side-Effects
Software & Forms
Resources & Links
Donate Helpline Decision
Aide About
Us Español 
Newsletter PCRI
Papers Resources Search
General Prostate Cancer NewsPCRI is pleased to provide general prostate cancer news items courtesy of CancerConsultants.com Inc. whose mission is “to empower patients with current information on all aspects of the management of Prostate Cancer in order to provide support and hope, as well as to facilitate informed decisions”.
Latest Prostate Cancer NewsStudy Explores Prostate Cancer Among Men with Low PSA Levels (7/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.Statins May Reduce Risk of Prostate Cancer Recurrence (7/2/2010)
Statin use may reduce the risk of prostate cancer recurrence among men who have undergone a radical prostatectomy. These findings were recently published in the journal Cancer.Watchful Waiting May Be Sufficient in Low-risk Prostate Cancer (6/30/2010)
Active surveillance—sometimes referred to as “watchful waiting”—may be acceptable treatment for low-risk prostate cancer, according to the results of a study published early online in the Journal of the National Cancer Institute.Jevtana Approved for Hormone-refractory Prostate Cancer (6/21/2010)
Jevtana® (cabazitaxel), a new chemotherapy drug, was approved for use in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer previously treated with a Taxotere® (docetaxel)-containing regimen.Addition of Radiation to Hormone Therapy Improves Survival in Locally Advanced Prostate Cancer (6/8/2010)
The addition of radiation therapy to hormone therapy reduces the risk of prostate cancer death by 43% among men with locally advanced or high-risk prostate cancer compared with hormone therapy alone, according to the results of a phase III study presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Copyright ©2005 CancerConsultants.com. All Rights Reserved.
General Prostate Cancer News Archives
Prostate Cancer Research Institute (PCRI)
Material provided by PCRI is intended for educational purposes for discussion with your physician and should not be considered as medical advice. Information and opinions expressed on this website are not an endorsement by PCRI for any treatment, product or service.